With the implementation of China's universal two-child policy and a notable rise in adverse pregnancy outcomes, leveraging electronic health records (EHR) has become crucial for enhancing maternal health. Given the mature construction of the information platform and the well-established maternal and child health service system in Jiangsu Province, this study used the Jiangsu Health Information Platform to carry out the research on the JiAngSu Maternal and INfant hEalth database (JASMINE), which involved over 1.5 million mother-child pairs in Jiangsu Province. JASMINE enables longitudinal follow-up of pregnant women and their offspring, facilitating the exploration of early-life exposures and their long-term outcomes through comprehensive data linkage. This longitudinal approach helps to clarify the relationship and etiological significance of risk factors associated with adverse pregnancy outcomes.It also permits the exploration of the health trajectory of women and children throughout their lives. From January 2020 to December 2023, JASMINE has recorded extensive maternal and child health data, including socio-demographics, healthcare services, medications, and clinical outcomes.Additionally, it contains longitudinal measurements on risk factors for adverse pregnancy outcomes, which provides a robust foundation for future real-world studies of dynamic predictive models. This study has been approved approved by the Institutional Review Board of Nanjing Medical University. Ultimately, this research aims to identify key predictors of adverse pregnancy outcomes and inform public health policies to improve maternal and child health in Jiangsu Province. Future directions will include developing targeted interventions based on study findings to enhance health outcomes for mothers and infants.
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Incidence of preterm birth
Timeframe: Up to 42 weeks
Incidence of pre-eclampsia
Timeframe: Up to 42 weeks
Incidence of eclampsia
Timeframe: Up to 42 weeks
Incidence of gestational diabetes mellitus
Timeframe: Up to 42 weeks
Incidence of low birth weight
Timeframe: Up to 42 weeks
Incidence of small for gestational age
Timeframe: Up to 42 weeks
Incidence of autism
Timeframe: Up to 10 years
Incidence of birth defects
Timeframe: Up to 10 years
Incidence of postpartum hemorrhage
Timeframe: Within 24 hours after delivery
Incidence of stillbirth
Timeframe: Up to 42 weeks
Incidence of ruptured uterus
Timeframe: Up to 42 weeks
Incidence of maternal death
Timeframe: Up to 52 weeks
Incidence of neonatal death
Timeframe: Within 28 days after delivery